Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) Positivity in Cervical Cancer Screening of Women in a Peri-Urban Area in Andhra Pradesh, India

SHARE INDIA, Mediciti Institute for Medical Sciences, Ghanpur, India.
Cancer Epidemiology Biomarkers & Prevention (Impact Factor: 4.32). 05/2010; 19(5):1373-80. DOI: 10.1158/1055-9965.EPI-09-1282
Source: PubMed

ABSTRACT Visual inspection of the cervix after acetic acid application (VIA) is widely recommended as the method of choice in cervical cancer screening programs in resource-limited settings because of its simplicity and ability to link with immediate treatment. In testing the effectiveness of VIA, human papillomavirus DNA testing, and Pap cytology in a population-based study in a peri-urban area in Andhra Pradesh, India, we found the sensitivity of VIA for detection of cervical intraepithelial neoplasia grade 2 and worse (CIN2+) to be 26.3%, much lower than the 60% to 90% reported in the literature. We therefore investigated the determinants of VIA positivity in our study population.
We evaluated VIA positivity by demographics and reproductive history, results of clinical examination, and results from the other screening methods.
Of the 19 women diagnosed with CIN2+, only 5 were positive by VIA (positive predictive value, 3.1%). In multivariate analysis, VIA positivity (12.74%) was associated with older age, positive Pap smear, visually apparent cervical inflammation, and interobserver variation. Cervical inflammation of unknown cause was present in 21.62% of women. In disease-negative women, cervical inflammation was associated with an increase in VIA positivity from 6.1% to 15.5% (P<0.001). Among the six gynecologists who performed VIA, the positivity rate varied from 4% to 31%.
The interpretation of VIA is subjective and its performance cannot be readily evaluated against objective standards.
VIA is not a robust screening test and we caution against its use as the primary screening test in resource-limited regions.

Download full-text


Available from: Michelle I Silver, Jun 27, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pyrazine (pz) reacts with Zeise's salt and its bromo and iodo analogues, K[PtX3-(CH2CH2)] (X  Cl, Br, I) to form two series of complexes: trans-[PtX2(CH2CH2)(pz)] (I) and trans-[Pt2X4(CH2CH2)2(pz)] (II). The 1H NMR spectra reveal that the pyrazine in type (I) complexes is fluxional since the aromatic proton resonance is a singlet. The value of JPtH is consistent with trans-coordination. IR bands are assigned by deuteration of the ethylene and pyrazine and by varying the coordinated halide. The antisymmetric νPtC2 band occurs near 470 cm−1 while νPtN is near 200 cm−1. In type (II) complexes the infrared-forbidden symmetric νPtC2 band is observed near 400 cm−1 while νPtN is strongly halogen-dependent. The electronic spectra reveal a X− → Pt2+ charge transfer band at 240 nm and a combined π → π∗ (pyrazine) and π → π∗ (ethylene) band near 270 nm. The 5d → π∗ (pz) and 5d → π∗ (ethylene) transitions yield a broad envelope in the spectra of type (I) complexes near 320 nm. This becomes resolved into two components in type (II) spectra.
    Journal of Molecular Structure 04/1983; 98(3-4-98):315-321. DOI:10.1016/0022-2860(83)90128-X · 1.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The plasma opening switch (POS) has been used for vacuum power conditioning in pulsed power systems. In this work, we report on experiments coupling a 0.5-MA and 3-MA conduction-current,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cervical disease burden continues to be especially high in HIV-infected women, even in the era of effective antiretroviral medications. This review discusses the multiple issues surrounding HIV-associated cervical cancer. Also, the unique treatment-related issues in HIV-associated cervical cancer are addressed. The incidence of invasive cervical cancer has remained stable in industrialized nations; however, it is only estimated in developing countries secondary to a relative lack of data collection and registries. Trends in HIV-associated cervical cancer have changed in the highly active antiretroviral therapy (HAART) era. Recent molecular pathways suggest that the natural progression of human papillomavirus infection, the causal agent in all cervical cancers, may be related to immune system dysfunction as well as HIV/human papillomavirus synergistic mechanisms. When highly active retroviral therapies are used, invasive cervical cancer treatments are impacted by concomitant drug toxicities that could potentially limit therapeutic benefit of either HAART or the standard of care treatment for locally advanced cervical cancer, concomitant chemoradiotherapy. The significance and care of the patient with invasive cervical cancer is becoming a geographically relevant phenomenon such that it may be time to re-address the global definition. Further studies in treatment issues and drug-drug interactions with cervical cancer treatments in the setting of HIV are paramount.
    Current opinion in oncology 09/2010; 22(5):449-55. DOI:10.1097/CCO.0b013e32833cff4f · 3.76 Impact Factor